Widmox-CV LB Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores, designed to provide broad-spectrum antibacterial activity while supporting gastrointestinal health. Amoxycillin, a beta-lactam antibiotic, acts by inhibiting bacterial cell wall synthesis, effectively targeting a wide range of Gram-positive and Gram-negative bacteria. Clavulanic Acid serves as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacterial strains, thereby enhancing its efficacy against beta-lactamase-producing pathogens. The inclusion of Lactobacillus, a probiotic microorganism, helps restore and maintain normal gut flora balance, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances commonly associated with antibiotic therapy. Widmox-CV LB is indicated for the treatment of various infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. It is essential to administer the tablet as prescribed, typically with meals to improve absorption and minimize gastrointestinal discomfort. Caution is advised in patients with a history of hypersensitivity to penicillins or beta-lactam antibiotics. Use during pregnancy and lactation should be under medical supervision. This combination therapy offers an effective approach to managing bacterial infections while mitigating adverse effects on intestinal microbiota.